Drug Profile
Research programme: small molecule therapeutics - Snowdon
Alternative Names: SND-121; SND-159; SND-226Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Snowdon
- Developer Snowdon; University of Chicago Pritzker School of Medicine; University of Medicine & Dentistry of New Jersey
- Class Analgesics; Small molecules
- Mechanism of Action Glutamate receptor modulators; Glutamate release inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurological disorders; Neuropathic pain; Toxoplasmosis; Tuberculosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Neurological-disorders in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Neuropathic-pain in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Toxoplasmosis in USA